ENANTA PHARMACEUTICALS, INC: stockholders equity
Stockholders equity for ENANTA PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ENANTA PHARMACEUTICALS, INC financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-09-30 to 2025-09-30. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-09-30 | 64,717,000 | USD | 2025-11-19 | 10-K · 0001193125-25-288121 |
| At date | 2024-09-30 | 128,814,000 | USD | 2025-11-19 | 10-K · 0001193125-25-288121 |
| At date | 2023-09-30 | 216,735,000 | USD | 2025-11-19 | 10-K · 0001193125-25-288121 |
| At date | 2022-09-30 | 321,334,000 | USD | 2025-11-19 | 10-K · 0001193125-25-288121 |
| At date | 2021-09-30 | 399,429,000 | USD | 2024-11-27 | 10-K · 0000950170-24-131260 |
| At date | 2020-09-30 | 455,580,000 | USD | 2023-11-22 | 10-K · 0000950170-23-065884 |
| At date | 2019-09-30 | 462,492,000 | USD | 2022-11-23 | 10-K · 0000950170-22-025667 |
| At date | 2018-09-30 | 393,679,000 | USD | 2021-11-24 | 10-K · 0000950170-21-004895 |
| At date | 2017-09-30 | 301,676,000 | USD | 2020-11-25 | 10-K · 0001564590-20-055233 |
| At date | 2016-09-30 | 269,936,000 | USD | 2019-11-27 | 10-K · 0001564590-19-044729 |
| At date | 2015-09-30 | 236,157,000 | USD | 2018-11-29 | 10-K · 0001564590-18-030275 |
| At date | 2014-09-30 | 148,654,000 | USD | 2017-12-11 | 10-K · 0001564590-17-024794 |
| At date | 2013-09-30 | 110,468,000 | USD | 2016-12-09 | 10-K · 0001193125-16-789660 |
| At date | 2012-09-30 | -115,353,000 | USD | 2015-12-11 | 10-K · 0001193125-15-401602 |
| At date | 2011-09-30 | -131,961,000 | USD | 2014-12-11 | 10-K · 0001193125-14-440235 |
| At date | 2010-09-30 | -150,075,000 | USD | 2013-12-18 | 10-K · 0001193125-13-477878 |
Related financial histories
- ENANTA PHARMACEUTICALS, INC: total assets
- ENANTA PHARMACEUTICALS, INC: total liabilities
- ENANTA PHARMACEUTICALS, INC: cash and cash equivalents
- ENANTA PHARMACEUTICALS, INC: net income or loss
- ENANTA PHARMACEUTICALS, INC: operating cash flow
- ENANTA PHARMACEUTICALS, INC: capital expenditure payments
- ENANTA PHARMACEUTICALS, INC: revenue
- ENANTA PHARMACEUTICALS, INC: contract revenue excluding tax
- ENANTA PHARMACEUTICALS, INC: financing cash flow
- ENANTA PHARMACEUTICALS, INC: investing cash flow
- ENANTA PHARMACEUTICALS, INC: retained earnings or deficit
- ENANTA PHARMACEUTICALS, INC: basic weighted-average shares
- ENANTA PHARMACEUTICALS, INC: diluted weighted-average shares
- ENANTA PHARMACEUTICALS, INC: basic earnings per share
- ENANTA PHARMACEUTICALS, INC: diluted earnings per share
- ENANTA PHARMACEUTICALS, INC: income tax expense or benefit
- ENANTA PHARMACEUTICALS, INC: net property, plant and equipment
- ENANTA PHARMACEUTICALS, INC: share-based compensation expense
- ENANTA PHARMACEUTICALS, INC: operating income or loss
- ENANTA PHARMACEUTICALS, INC: current assets
- ENANTA PHARMACEUTICALS, INC: interest expense
- ENANTA PHARMACEUTICALS, INC: current liabilities
- ENANTA PHARMACEUTICALS, INC: current accounts payable
- ENANTA PHARMACEUTICALS, INC: net current accounts receivable
- ENANTA PHARMACEUTICALS, INC: research and development expense
Inspect the source
- Entity
- ENANTA PHARMACEUTICALS, INC / CIK 0001177648
- Captured
- 2026-09-20T07:44:57.103Z
- SEC response SHA-256
80fddde6209a85211c99bf9c410a8d05c029ccda8597cc49f72b1775c18d6d7b
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001177648.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))